Curaleaf Acquires EMMAC Life Sciences
March 9, 2021
Curaleaf Holdings announced a definitive agreement to acquire EMMAC Life Sciences Limited for approximately US$286 million (85% in Curaleaf shares, 15% cash) plus up to US$57 million of contingent earn-outs. The acquisition gives Curaleaf a developed, vertically integrated platform for entry into the European medical cannabis market, including cultivation, EU‑GMP processing, distribution and R&D across key EU markets.
- Buyers
- Curaleaf Holdings, Inc.
- Targets
- EMMAC Life Sciences Limited
- Industry
- Healthcare Services
- Location
- England, United Kingdom
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.